Protocol Ledger

Clinical Cooperative Network · Consolidated Sponsor Hub

Children's Oncology Group: Clinical Trials & FDA Approval Profile

Children's Oncology Group (Global / Institutional) sponsors 42 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 37 active protocols (19 recruiting now), 1 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.5%
Median Closed Enrollment vs National (145 pts)41 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Children's Oncology Group
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)42
Active Pipeline (Recruiting Now)37 (19)
Completed vs Stopped Early1 / 4 (9.5%)
Median Closed Actual Enrollment41 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Children's Oncology Group
Hospital Research SiteLocationShared Protocols
Riley Hospital for ChildrenIndianapolis, IN35
Children's Hospital ColoradoAurora, CO34
Children's Hospital of AlabamaBirmingham, AL34

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Children's Oncology Group
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07022678Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid LeukemiaPhase IIIRECRUITING
NCT05711667A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric PatientsPhase IIIRECRUITING
NCT05504291A Study to Give Treatment Inside the Eye to Treat RetinoblastomaPhase IIRECRUITING
NCT06368817A Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaPhase IIRECRUITING
NCT05304585Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Children's Oncology Group Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI